We hypothesised these SEs could be potentiated by the reactivation of such dormant enhancers in response to p52 binding during constitutive NF-κB signalling and subsequently impacting the putative target gene expression in myeloma cells. Here, NFKB1 is linked to plasma cell myeloma.